A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.
After measles vaccine (MV), all-cause mortality is reduced more than can be explained by the prevention of measles, especially in females.We aimed to study the biological mechanisms underlying the observed non-specific and sex-differential effects of MV on mortality.Within a large randomised trial o...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4024025?pdf=render |
id |
doaj-a45f6a87a33c4d04bd22efc39e9a5c1c |
---|---|
record_format |
Article |
spelling |
doaj-a45f6a87a33c4d04bd22efc39e9a5c1c2020-11-24T22:03:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9753610.1371/journal.pone.0097536A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.Kristoffer Jarlov JensenMia SøndergaardAndreas AndersenErliyani SartonoCesario MartinsMay-Lill GarlyJesper Eugen-OlsenHenrik UllumMaria YazdanbakhshPeter AabyChristine Stabell BennChristian ErikstrupAfter measles vaccine (MV), all-cause mortality is reduced more than can be explained by the prevention of measles, especially in females.We aimed to study the biological mechanisms underlying the observed non-specific and sex-differential effects of MV on mortality.Within a large randomised trial of MV at 4.5 months of age blood samples were obtained before and six weeks after randomisation to early MV or no early MV. We measured concentrations of cytokines and soluble receptors from plasma (interleukin-1 receptor agonist (IL-1Ra), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1, soluble urokinase-type plasminogen activator receptor), and secreted cytokines (interferon-γ, TNF-α, IL-5, IL-10, IL-13, IL-17) after in vitro challenge with innate agonists and recall antigens. We analysed the effect of MV in multiple imputation regression, overall and stratified by sex. The majority of the infants had previously been enrolled in a randomised trial of neonatal vitamin A. Post hoc we explored the potential effect modification by neonatal vitamin A.Overall, MV versus no MV was associated with higher plasma MCP-1 levels, but the effect was only significant among females. Additionally, MV was associated with increased plasma IL-1Ra. MV had significantly positive effects on plasma IL-1Ra and IL-8 levels in females, but not in males. These effects were strongest in vitamin A supplemented infants. Vitamin A shifted the effect of MV in a pro-inflammatory direction.In this explorative study we found indications of sex-differential effects of MV on several of the plasma biomarkers investigated; in particular MV increased levels in females, most strongly in vitamin A recipients. The findings support that sex and micronutrient supplementation should be taken into account when analysing vaccine effects.clinicaltrials.gov number NCT 00168545.http://europepmc.org/articles/PMC4024025?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kristoffer Jarlov Jensen Mia Søndergaard Andreas Andersen Erliyani Sartono Cesario Martins May-Lill Garly Jesper Eugen-Olsen Henrik Ullum Maria Yazdanbakhsh Peter Aaby Christine Stabell Benn Christian Erikstrup |
spellingShingle |
Kristoffer Jarlov Jensen Mia Søndergaard Andreas Andersen Erliyani Sartono Cesario Martins May-Lill Garly Jesper Eugen-Olsen Henrik Ullum Maria Yazdanbakhsh Peter Aaby Christine Stabell Benn Christian Erikstrup A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. PLoS ONE |
author_facet |
Kristoffer Jarlov Jensen Mia Søndergaard Andreas Andersen Erliyani Sartono Cesario Martins May-Lill Garly Jesper Eugen-Olsen Henrik Ullum Maria Yazdanbakhsh Peter Aaby Christine Stabell Benn Christian Erikstrup |
author_sort |
Kristoffer Jarlov Jensen |
title |
A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. |
title_short |
A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. |
title_full |
A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. |
title_fullStr |
A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. |
title_full_unstemmed |
A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. |
title_sort |
randomized trial of an early measles vaccine at 4½ months of age in guinea-bissau: sex-differential immunological effects. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
After measles vaccine (MV), all-cause mortality is reduced more than can be explained by the prevention of measles, especially in females.We aimed to study the biological mechanisms underlying the observed non-specific and sex-differential effects of MV on mortality.Within a large randomised trial of MV at 4.5 months of age blood samples were obtained before and six weeks after randomisation to early MV or no early MV. We measured concentrations of cytokines and soluble receptors from plasma (interleukin-1 receptor agonist (IL-1Ra), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1, soluble urokinase-type plasminogen activator receptor), and secreted cytokines (interferon-γ, TNF-α, IL-5, IL-10, IL-13, IL-17) after in vitro challenge with innate agonists and recall antigens. We analysed the effect of MV in multiple imputation regression, overall and stratified by sex. The majority of the infants had previously been enrolled in a randomised trial of neonatal vitamin A. Post hoc we explored the potential effect modification by neonatal vitamin A.Overall, MV versus no MV was associated with higher plasma MCP-1 levels, but the effect was only significant among females. Additionally, MV was associated with increased plasma IL-1Ra. MV had significantly positive effects on plasma IL-1Ra and IL-8 levels in females, but not in males. These effects were strongest in vitamin A supplemented infants. Vitamin A shifted the effect of MV in a pro-inflammatory direction.In this explorative study we found indications of sex-differential effects of MV on several of the plasma biomarkers investigated; in particular MV increased levels in females, most strongly in vitamin A recipients. The findings support that sex and micronutrient supplementation should be taken into account when analysing vaccine effects.clinicaltrials.gov number NCT 00168545. |
url |
http://europepmc.org/articles/PMC4024025?pdf=render |
work_keys_str_mv |
AT kristofferjarlovjensen arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT miasøndergaard arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT andreasandersen arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT erliyanisartono arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT cesariomartins arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT maylillgarly arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT jespereugenolsen arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT henrikullum arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT mariayazdanbakhsh arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT peteraaby arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT christinestabellbenn arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT christianerikstrup arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT kristofferjarlovjensen randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT miasøndergaard randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT andreasandersen randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT erliyanisartono randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT cesariomartins randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT maylillgarly randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT jespereugenolsen randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT henrikullum randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT mariayazdanbakhsh randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT peteraaby randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT christinestabellbenn randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects AT christianerikstrup randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects |
_version_ |
1725831263137300480 |